Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept for Moderately Sensitized Kidney Transplant Patients
NCT02130817Phase 4Withdrawn
- Sponsor
- University of Wisconsin–Madison
- Start
- Sep 2014
- Primary completion
- Oct 2015
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of belatacept in kidney transplant rejection, delayed graft function (DGF), sponsored by University of Wisconsin–Madison. Planned start Sep 2014; status: withdrawn.
02
Drugs
belatacept
03
Conditions
kidney transplant rejectiondelayed graft function (DGF)
Beyond the preview
Go deeper on NCT02130817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130817.